AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
9 articles.
Bangladesh All Bangladesh research →
Company · DSE:UNIONINS · Insurance · Analysis · 02 Nov 2026
Union Insurance: 2025 EPS Tk 1.90, combined ratio 77.6%, qualified opinion and Tk 968.0m due from Sadharan Bima
A Dhaka non-life insurer with Tk 931.0m of equity at 31-Dec-2025. 2025 net premium was Tk 721.1m, underwriting profit Tk 121.9m and EPS Tk 1.90; the auditor qualified the opinion on claims, balances with other insurers and tax.
Company · DSE:JANATAINS · Insurance · Analysis · 02 Nov 2026
Janata Insurance: 2025 EPS Tk 1.10, combined ratio 78.5% and Tk 353.0m due from Sadharan Bima
A Dhaka general insurer with Tk 730.8m of equity and Tk 678.9m of cash and bank balances. 2025 net premium rose 7.8% to Tk 445.9m and EPS was Tk 1.10; the auditor's opinion is unmodified with three emphases of matter and three key audit matters.
Company · DSE:UNITEDINS · Insurance · Analysis · 02 Nov 2026
United Insurance: 2025 EPS Tk 3.46, combined ratio 60.1% and a Tk 426.8m United Finance stake
A Dhaka general insurer with Tk 1.38bn of equity, controlled since November 2024 by United Group shareholders. 2025 net premium rose 48.0% to Tk 438.2m and EPS was Tk 3.46; the auditor's opinion is unmodified with four key audit matters.
Company · DSE:MERCINS · Insurance · Analysis · 01 Nov 2026
Mercantile Islami Insurance: fire claims of Tk 181.7m, combined ratio 110.7% and 2025 EPS Tk 1.65
A Dhaka general insurer with Tk 935m of equity and Tk 1.06bn in FDRs. 2025 net premium fell 29.6% to Tk 273.8m, fire lost Tk 144.2m and EPS was Tk 1.65; the auditor added four emphasis-of-matter bullets.
Company · DSE:PHARMAID · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Pharma Aids: FY2025 net sales of BDT 438m, 9M FY2026 sales up 17.6% and profit up 28.1%, sponsors at 19.38%
Bangladesh's listed maker of neutral glass ampoules for drug companies: seven years of filings, a 30.3% gross margin, BDT 27.3m of borrowings at June 2025, an auditor's opinion worded 'except for', and FY2026 results due to the board on 3-Nov-2026.
Company · DSE:REPUBLIC · Insurance · Analysis · 29 Oct 2026
Republic Insurance: qualified 2025 audit, combined ratio 79.4% and Tk 799.7m due from SBC
A general insurer: in 2025 marine cargo made Tk 115.9m of underwriting profit and total underwriting profit was Tk 105.9m. The auditor qualified the 2025 accounts over gratuity, expected credit loss and unconfirmed SBC balances. EPS was Tk 1.88; nine-month 2026 EPS was Tk 1.45 against Tk 1.47.
Company · DSE:FEDERALINS · Insurance · Analysis · 29 Oct 2026
Federal Insurance: qualified 2025 audit opinion, gross premium down 4.8% and EPS Tk 1.10
A Dhaka general insurer with Tk 926m of equity and no bank borrowings. 2025 gross premium was Tk 615.4m and EPS Tk 1.10; the auditor qualified the 2025 opinion over an agent balance of Tk 117.1m; nine-month 2026 EPS was Tk 1.16 against Tk 0.85 (DSE).
Company · DSE:CENTRALINS · Insurance · Analysis · 29 Oct 2026
Central Insurance: adverse audit opinion on 2025, combined ratio up to 79.8% and nine-month 2026 EPS of Tk 1.79
A Dhaka general insurer with Tk 697m of cash and deposits and Tk 1.5bn of property revaluation in equity. Its auditor gave an adverse opinion on 2025; EPS was Tk 1.87, and nine-month 2026 EPS was Tk 1.79 against Tk 1.45.
Company · DSE:ORIONPHARM · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Orion Pharma: power revenue fell 88% after the plant contracts expired, leaving a BDT 25.6bn debt load on a pharma business earning BDT 251m
FY2025 consolidated revenue fell 61.6% to BDT 4.08bn and the group lost BDT 415m. The auditor qualified its opinion over a restated UCB loan and a BDT 651m claim on an individual; the shares have been in DSE's Z category since 5-Feb-2025 over an unpaid dividend.